Kathleen Ford Biography and Net Worth

Chief Operating Officer of Kura Oncology

Ms. Ford joined Kura as Chief Operating Officer in August 2019 with more than 30 years of biopharmaceutical experience supporting pipeline development. She was most recently Senior Vice President, Head of Global Clinical Operations, at Merck Serono, a division of Merck KGaA, where she led clinical and development operations toward successful drug registrations in both the U.S. and Europe. Previously, she served in roles of increasing responsibility at Millennium Pharmaceuticals, most recently as Vice President, Clinical Operations, where she led the global operational management of clinical trial activities in all phases of development. Prior to that, she served as Director of Clinical Operations at Alkermes, where she managed the clinical development for two product approvals. Ms. Ford earned her R.N. from Massachusetts General Hospital School of Nursing and her B.S.N. from Fitchburg State College.

What is Kathleen Ford's net worth?: The estimated net worth of Kathleen Ford is at least $1.26 million as of November 14th, 2025. Ms. Ford owns 105,373 shares of Kura Oncology stock worth more than $1,262,369 as of December 5th. This net worth evaluation does not reflect any other investments that Ms. Ford may own. Additionally, Ms. Ford receives an annual salary of $824,950.00 as Chief Operating Officer at Kura Oncology. Learn More about Kathleen Ford's net worth.
How old is Kathleen Ford?: Ms. Ford is currently 77 years old. There are 5 older executives and no younger executives at Kura Oncology. Learn More on Kathleen Ford's age.
What is Kathleen Ford's salary?: As the Chief Operating Officer of Kura Oncology, Inc., Ms. Ford earns $824,950.00 per year. There are 2 executives that earn more than Ms. Ford. The highest earning executive at Kura Oncology is Dr. Troy Edward Wilson J.D., Ph.D., Chairman, CEO & President, who commands a salary of $1,220,000.00 per year. Learn More on Kathleen Ford's salary.
How do I contact Kathleen Ford?: The corporate mailing address for Ms. Ford and other Kura Oncology executives is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. Kura Oncology can also be reached via phone at (858) 500-8800 and via email at [email protected]. Learn More on Kathleen Ford's contact information.
Has Kathleen Ford been buying or selling shares of Kura Oncology?: During the past quarter, Kathleen Ford has sold $77,164.36 in Kura Oncology stock. Most recently, Kathleen Ford sold 6,902 shares of the business's stock in a transaction on Friday, November 14th. The shares were sold at an average price of $11.18, for a transaction totalling $77,164.36. Following the completion of the sale, the chief operating officer now directly owns 105,373 shares of the company's stock, valued at $1,178,070.14. Learn More on Kathleen Ford's trading history.
Who are Kura Oncology's active insiders?: Kura Oncology's insider roster includes Teresa Bair (Chief Legal Officer), Thomas Doyle (SVP, Finance and Accounting), Kathleen Ford (Chief Operating Officer), Laura Johnson (Director), Mollie Leoni (Chief Medical Officer), Thomas Malley (Director), Anthony Praill (CFO), Troy Wilson (President and Chief Executive Officer), and Saiid Zarrabian (Insider). Learn More on Kura Oncology's active insiders.
Are insiders buying or selling shares of Kura Oncology?: In the last twelve months, Kura Oncology insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $410,000.00. In the last twelve months, insiders at the sold shares 16 times. They sold a total of 137,521 shares worth more than $1,308,039.69. The most recent insider tranaction occured on November, 14th when insider Teresa Brophy Bair sold 8,804 shares worth more than $98,428.72. Insiders at Kura Oncology own 6.4% of the company. Learn More about insider trades at Kura Oncology.
Information on this page was last updated on 11/14/2025.

Kathleen Ford Insider Trading History at Kura Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/14/2025	Sell	6,902	$11.18	$77,164.36	105,373
9/29/2025	Sell	6,892	$8.94	$61,614.48	63,375
5/19/2025	Sell	1,558	$6.28	$9,784.24	21,367
1/28/2025	Sell	1,817	$7.87	$14,299.79	21,367
11/18/2024	Sell	526	$16.03	$8,431.78	23,184
1/29/2024	Sell	1,496	$17.80	$26,628.80	21,602
1/27/2023	Sell	1,821	$13.89	$25,293.69	21,214
3/15/2021	Sell	6,250	$29.43	$183,937.50	6,250
11/10/2020	Sell	6,250	$39.43	$246,437.50	6,250
9/14/2020	Sell	6,250	$29.43	$183,937.50	6,250

Kathleen Ford Buying and Selling Activity at Kura Oncology

Kura Oncology Company Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $11.98

$11.90

$12.32

50 Day Range

MA: $10.37

$8.85

$12.09

2 Week Range

Now: $11.98

$5.41

$12.49

Volume

1,438,355 shs

Average Volume

1,795,837 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Kathleen Ford Biography and Net Worth

What is Kathleen Ford's net worth?

How old is Kathleen Ford?

What is Kathleen Ford's salary?

How do I contact Kathleen Ford?

Has Kathleen Ford been buying or selling shares of Kura Oncology?

Who are Kura Oncology's active insiders?

Are insiders buying or selling shares of Kura Oncology?